TABLE 2.
Antiproliferative and some other kinase inhibitory activities of compound 17l.
| Compound | IC50 (μM) | |||||
|---|---|---|---|---|---|---|
| c-Met | VEGFR-2 | EGFRWT | PC-9 | H460 | H1975 | |
| 17l | 0.026 | 2.6 | >10 | 38.25 ± 1.58 | 5.86 ± 0.77 | 15.30 ± 1.18 |
| Staurosporine a | 0.125 | - | - | ND c | ND | ND |
| Sorafenib b | ND | ND | ND | 5.41 ± 0.73 | 5.27 ± 0.72 | 10.18 ± 1.00 |
Note. VEGFR, vascular endothelial growth factor receptor; PC-9, exon 19 of EGFR; H1975, gefitinib cell line; H460, human non-small cell lung cancer cells.
a
Used as a positive control.
b
Used as a positive control.
c
ND, not detected.